Robert C Janzer
Overview
Explore the profile of Robert C Janzer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
17516
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bougel S, Lhermitte B, Gallagher G, de Flaugergues J, Janzer R, Benhattar J
Clin Cancer Res
. 2013 Feb;
19(8):2216-23.
PMID: 23444211
Purpose: The diagnosis of leptomeningeal metastases is usually confirmed by the finding of malignant cells by cytologic examination in the cerebrospinal fluid (CSF). More sensitive and specific cancer biomarkers may...
2.
Clemessy M, Janzer R, Lhermitte B, Gasc J, Juillerat-Jeanneret L
J Neurooncol
. 2011 Oct;
107(1):29-36.
PMID: 21979892
Brain tumors, benign or malignant, are characterized by a very high degree of vascularization. Recent accumulating evidence suggests that during development the neuronal wiring follows the same routes as the...
3.
Mataftsi A, Zografos L, Balmer A, Uffer S, Stupp R, Janzer R, et al.
Ophthalmic Genet
. 2011 Apr;
33(3):155-8.
PMID: 21526971
Purpose: To report the lethal course of malignant transformation of retinoma in an adult. Methods: Case report. A 40-year-old patient presented with retinoma in his right eye and retinoblastoma in...
4.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R, et al.
Lancet Oncol
. 2009 Mar;
10(5):459-66.
PMID: 19269895
Background: In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported...
5.
Fiaux H, Kuntz D, Hoffman D, Janzer R, Gerber-Lemaire S, Rose D, et al.
Bioorg Med Chem
. 2008 Jul;
16(15):7337-46.
PMID: 18599296
Refining the chemical structure of functionalized pyrrolidine-based inhibitors of Golgi alpha-mannosidase II (GMII) to optimize binding affinity provided a lead molecule that demonstrated nanomolar competitive inhibition of alpha-mannosidases II and...
6.
Juillerat-Jeanneret L, Chapuis Bernasconi C, Bricod C, Gros S, Trepey S, Benhattar J, et al.
Cancer Invest
. 2008 Jun;
26(6):597-609.
PMID: 18584351
The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment. The methylation of MGMT promoter and the...
7.
Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M, et al.
N Engl J Med
. 2005 Mar;
352(10):997-1003.
PMID: 15758010
Background: Epigenetic silencing of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma who receive alkylating...
8.
Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M, et al.
N Engl J Med
. 2005 Mar;
352(10):987-96.
PMID: 15758009
Background: Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible,...
9.
Stupp R, Janzer R, Hegi M, Villemure J, Mirimanoff R
Semin Oncol
. 2004 Feb;
30(6 Suppl 19):23-8.
PMID: 14765381
Low-grade gliomas are a heterogenous group of diseases characterized by relatively slow-growing primary brain tumors of astrocytic and/or oligodendroglial origin. Many patients present with easily controlled seizures and remain stable...
10.
Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, et al.
Cancer Res
. 2003 Oct;
63(20):6613-25.
PMID: 14583454
The development of targeted treatment strategies adapted to individual patients requires identification of the different tumor classes according to their biology and prognosis. We focus here on the molecular aspects...